250 related articles for article (PubMed ID: 19029516)
61. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
[TBL] [Abstract][Full Text] [Related]
62. Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial.
Chen PC; Hsieh YC; Huang CC; Hu CJ
Medicine (Baltimore); 2020 May; 99(22):e20423. PubMed ID: 32481440
[TBL] [Abstract][Full Text] [Related]
63. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
64. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Corbo M; Lunetta C; Magni P; Dozio E; Ruscica M; Adobbati L; Silani V
Eur J Neurol; 2010 Mar; 17(3):398-404. PubMed ID: 19845745
[TBL] [Abstract][Full Text] [Related]
65. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
66. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
67. Trial of celecoxib in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Zhang H; Andreasson KI; Rothstein JD; Drachman DB
Ann Neurol; 2006 Jul; 60(1):22-31. PubMed ID: 16802291
[TBL] [Abstract][Full Text] [Related]
68. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
[TBL] [Abstract][Full Text] [Related]
69. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
70. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.
Weber M; Goldman B; Truniger S
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1135-40. PubMed ID: 20498181
[TBL] [Abstract][Full Text] [Related]
71. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis.
Hosback S; Hardiman O; Nolan CM; Doyle MA; Gorman G; Lynch C; O'Toole O; Jakeman P
Growth Horm IGF Res; 2007 Dec; 17(6):472-9. PubMed ID: 17697791
[TBL] [Abstract][Full Text] [Related]
72. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis.
Capozzo R; Quaranta VN; Pellegrini F; Fontana A; Copetti M; Carratù P; Panza F; Cassano A; Falcone VA; Tortelli R; Cortese R; Simone IL; Resta O; Logroscino G
J Neurol; 2015 Mar; 262(3):593-603. PubMed ID: 25522696
[TBL] [Abstract][Full Text] [Related]
73. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial.
Duning T; Schiffbauer H; Warnecke T; Mohammadi S; Floel A; Kolpatzik K; Kugel H; Schneider A; Knecht S; Deppe M; Schäbitz WR
PLoS One; 2011 Mar; 6(3):e17770. PubMed ID: 21423758
[TBL] [Abstract][Full Text] [Related]
74. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.
Lange DJ; Murphy PL; Diamond B; Appel V; Lai EC; Younger DS; Appel SH
Arch Neurol; 1998 Jan; 55(1):93-6. PubMed ID: 9443715
[TBL] [Abstract][Full Text] [Related]
75. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
Miller RG; Moore DH; Gelinas DF; Dronsky V; Mendoza M; Barohn RJ; Bryan W; Ravits J; Yuen E; Neville H; Ringel S; Bromberg M; Petajan J; Amato AA; Jackson C; Johnson W; Mandler R; Bosch P; Smith B; Graves M; Ross M; Sorenson EJ; Kelkar P; Parry G; Olney R;
Neurology; 2001 Apr; 56(7):843-8. PubMed ID: 11294919
[TBL] [Abstract][Full Text] [Related]
76. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial.
Kim S; Yang M; Ku B; Cha E; Seo W; Son I; Kang H; Kim D; Song B; Yang CS; Kim S
J Ethnopharmacol; 2023 Oct; 315():116670. PubMed ID: 37257710
[TBL] [Abstract][Full Text] [Related]
78. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Festoff BW; Yang SX; Vaught J; Bryan C; Ma JY
J Neurol Sci; 1995 May; 129 Suppl():114-21. PubMed ID: 7595601
[TBL] [Abstract][Full Text] [Related]
79. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
[TBL] [Abstract][Full Text] [Related]
80. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Kaufmann P; Thompson JL; Levy G; Buchsbaum R; Shefner J; Krivickas LS; Katz J; Rollins Y; Barohn RJ; Jackson CE; Tiryaki E; Lomen-Hoerth C; Armon C; Tandan R; Rudnicki SA; Rezania K; Sufit R; Pestronk A; Novella SP; Heiman-Patterson T; Kasarskis EJ; Pioro EP; Montes J; Arbing R; Vecchio D; Barsdorf A; Mitsumoto H; Levin B;
Ann Neurol; 2009 Aug; 66(2):235-44. PubMed ID: 19743457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
